

PRESS RELEASE
24 September, 2020



Enamine is selected for Horizon 2020 global project “AIDD” - Advanced Machine Learning for Innovative Drug Discovery" to boost Artificial Intelligence (AI) for chemistry and drug discovery

KIEV, Ukraine --Enamine Ltd., a leading chemical research organization and producer of the world's largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), has joined the Advanced Machine Learning for Innovative Drug Discovery (AIDD) program, funded by the European Union within the framework of the Marie-Skłodowska-Curie Actions (MSCA) with a budget of Euros 3.93 million. The project, coordinated by Helmholtz Zentrum München, Germany, brings together fifteen institutions from eleven countries in addition to the University of British Columbia (Canada) to train sixteen PhD students in close collaboration with associated partners from the USA, Australia, China, Israel and other countries and develop next generation AI and Machine Learning (ML) models and systems for drug discovery.

Within the project, Enamine as an industrial partner will provide its state of the art efficient chemical facilities, including technologies, unique resources and decades of research expertise in chemistry.

AI and ML are becoming an increasingly important working basis for the chemical and pharmaceutical industries. The aim of the new AIDD network is to prepare a future generation of scientists with outstanding skills in both ML and chemistry to innovate drug research.

PhD fellows participating in this training program will develop methods for predicting chemical reactivity and an interpretable multi-expert system for drug discovery, integrate microscopic images and structural information for the assessment of biological and toxic effects of molecules, and validate computational models for the design of new compounds. Via Helmholtz Zentrum München, students will also benefit in particular from the services offered by the recently launched Helmholtz-AI platform.

Michael Bossert Head of Strategic Alliances at Enamine commented "Enamine has already been involved in various EU funded research and educational initiatives with Horizon 2020-MSCA such as PELICO or joint PhD fellowship in Medicinal Chemistry projects. We are excited with the roll-out

of this new program and to deploy our infrastructure and skills to power the interest and knowledge of the group of PhD students participating - our drug discoverers of tomorrow with Artificial Intelligence as ally”.

With the Marie-Sklodowska-Curie Actions (MSCA), the European Union supports the international and cross-sectoral careers of scientists. The Innovative Training Networks (ITN) are the most prestigious projects of the MSCA with typical success rates of 5 to 10 percent.

Further information about AIDD can be found on the project website

ENDS

Contacts

Media:

Andrii Buvailo,
Head of Digital Marketing:
+38 066 047 75 87
a.buvailo@enamine.net

About Enamine Ltd.

Enamine Ltd. (est. 1991), a scientifically driven fully integrated service company, possesses the World's largest and most reputed stock collections of Building Blocks (225,000) and Screening compounds (2.7+ Million) and offers extensive portfolio of carefully designed Fragment Libraries, Discovery Diversity sets and Targeted Libraries. Enamine provides expertise in advanced organic synthesis, library synthesis, medicinal chemistry, HTS and pre-clinical biology to support research and development programs in life sciences and industries worldwide.